BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23374104)

  • 1. AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ.
    Tiyerili V; Becher UM; Aksoy A; Lütjohann D; Wassmann S; Nickenig G; Mueller CF
    Cardiovasc Diabetol; 2013 Feb; 12():30. PubMed ID: 23374104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
    Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
    Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice.
    Fukuda D; Enomoto S; Hirata Y; Nagai R; Sata M
    Biomed Pharmacother; 2010 Dec; 64(10):712-7. PubMed ID: 20970951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of peroxisome proliferator-activated receptor γ on angiotensin II type 1 receptor-mediated insulin sensitivity, vascular inflammation and atherogenesis in hypercholesterolemic mice.
    Tiyerili V; Becher UM; Camara B; Yildirimtürk C; Aksoy A; Kebschull M; Werner N; Nickenig G; Müller C
    Arch Med Sci; 2015 Aug; 11(4):877-85. PubMed ID: 26322101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
    Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
    Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
    Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
    Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
    Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
    Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M
    Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.
    Hu ZP; Fang XL; Qian HY; Fang N; Wang BN; Wang Y
    Fundam Clin Pharmacol; 2014 Oct; 28(5):501-11. PubMed ID: 24188213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms.
    Xuan H; Xu B; Wang W; Tanaka H; Fujimura N; Miyata M; Michie SA; Dalman RL
    J Vasc Surg; 2018 Feb; 67(2):573-584.e2. PubMed ID: 28434702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.
    Garrido-Gil P; Joglar B; Rodriguez-Perez AI; Guerra MJ; Labandeira-Garcia JL
    J Neuroinflammation; 2012 Feb; 9():38. PubMed ID: 22356806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
    Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
    Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
    Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
    Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.
    Zhang J; Liu X; Wang SQ; Liu GY; Xu WR; Cheng XC; Wang RL
    J Biomol Struct Dyn; 2017 Sep; 35(12):2665-2680. PubMed ID: 27602589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion.
    Washida K; Ihara M; Nishio K; Fujita Y; Maki T; Yamada M; Takahashi J; Wu X; Kihara T; Ito H; Tomimoto H; Takahashi R
    Stroke; 2010 Aug; 41(8):1798-806. PubMed ID: 20595663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
    Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice.
    Shiota A; Shimabukuro M; Fukuda D; Soeki T; Sato H; Uematsu E; Hirata Y; Kurobe H; Maeda N; Sakaue H; Masuzaki H; Shimomura I; Sata M
    Cardiovasc Diabetol; 2012 Nov; 11():139. PubMed ID: 23137106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.
    Walcher D; Hess K; Heinz P; Petscher K; Vasic D; Kintscher U; Clemenz M; Hartge M; Raps K; Hombach V; Marx N
    Hypertension; 2008 Feb; 51(2):259-66. PubMed ID: 18158351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
    Ihara Y; Egashira K; Nakano K; Ohtani K; Kubo M; Koga J; Iwai M; Horiuchi M; Gang Z; Yamagishi S; Sunagawa K
    J Mol Cell Cardiol; 2007 Oct; 43(4):455-64. PubMed ID: 17761193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.
    Goyal SN; Bharti S; Bhatia J; Nag TC; Ray R; Arya DS
    Diabetes Obes Metab; 2011 Jun; 13(6):533-41. PubMed ID: 21320264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.